XFOR News and Press, X4 Pharmaceuticals Inc. From 10/31/23

2023-10-31 10:35:43 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript X4 submits New Drug Application to FDA for WHIM syndrome drug ...

2023-10-31 10:04:17 ET DENVER, Colo., Oct. 31, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Cardio Diagnostics Holdings Inc (NASDAQ: CDIO), X4 Pharmaceuticals Inc (NASDAQ: XFOR), SciSparc Ltd (NASDAQ: ...

FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024 If the NDA is approved, company eligible to receive a Priority Review Voucher (PRV) resulting from mavorixafor’s rare pediatric designation in WHIM syndrome NDA supported by positive resu...

BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors. ...

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conferen...

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Morgan Stanley 21 st Annual G...

2023-09-05 12:07:16 ET More on X4 Pharmaceuticals Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pharmaceuticals Financial information for X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For...

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for...

2023-08-24 09:19:41 ET Summary X4 is nearing approval of its lead candidate for WHIM syndrome and aims for label expansion to a much larger market of chronic neutropenias. Despite very small WHIM target population, orphan designation (=premium pricing) and potential for non-diluti...

2023-08-10 13:25:55 ET Gainers: WeWork ( WE ) +87% . Capri Holdings Limited ( CPRI ) +56% . Black Spade Acquisition ( BSAQ ) +58% . Edible Garden AG Incorporated ( EDBL ) +43% . Lion Group Holding Ltd. ( LGHL ) +37% . Precige...